Investigators combined intratumoral STimulator of INterferon Genes (STING) agonist therapy with systemically injected extended half-life IL2 and anti–PD-1 checkpoint blockade to drive innate and adaptive antitumor immunity in models of triple-negative breast cancer.
[Cancer Immunology Research]
Sorry, but the selected Zotpress account can't be found.